We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Piqray

News List

EU regulators approve Novartis' breast cancer combo pharmatimes
July 31, 2020
European regulators have approved Novartis' Piqray (alpelisib) in combination with fulvestrant for the treatment of a certain type of breast cancer.
Novartis’ Piqray Approved as First PI3K Inhibitor for Breast Cancer drugs
June 03, 2019
Novartis’ Piqray Approved as First PI3K Inhibitor for Breast Cancer.
FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer drugs
May 31, 2019
FDA Approves Piqray.
FDA approval for Novartis’ Piqray pharmatimes
May 28, 2019
Novartis’ Piqray (alpelisib) has been approved by the US Food and Drug Administration (FDA) in combination with fulvestrant for the treatment of postmenopausal women and men with HR+ and HER2- PIK3CA-mutated, advanced or metastatic breast cancer.